GlaxoSmithKline, the U.K.’s biggest drugmaker, won U.S. approval for two skin cancer drugs targeted at patients most likely to respond to the medications. The Food and Drug Administration approved Tafinlar and Mekinist for patients with melanoma, the most dangerous form of skin cancer, that has spread or can’t be surgically removed. The drugs are aimed at patients who have certain gene mutations that need to be detected using a diagnostic test made by Marcy L’Etoile, France-based BioMerieux (BIM), which the FDA also cleared. Read the full story.